Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patients.

ABSTRACT: Bladder cancer (BlCa) exhibits a highly heterogeneous molecular landscape and treatment response, underlining the pressing need for personalized prognosis. N6-methyladenosine (m6A) constitutes the most abundant RNA modification, modulates RNA biology/metabolism, and maintains cellular homeostasis, with its dysregulation involved in cancer initiation and progression. Herein, we evaluated the clinical value of METTL3 m6A methyltransferase, the main catalytic component of m6A methylation machinery, in improving BlCa patients' risk stratification and prognosis. The screening cohort of the study included 213 patients. The UROMOL (n = 535) was analyzed as a validation cohort for non-muscle-invasive BlCa (NMIBC), while the TCGA-BLCA (n = 412) and Mariathasan et al. (n = 348) cohorts were analyzed

SUBMITTER: Pilala KM 

PROVIDER: S-EPMC12670348 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature